Fragile X syndrome with FMR1 and FMR2 deletion

S J Moore, L Strain, G F Cole, Z Miedzybrodzka, K F Kelly, J C S Dean

Abstract
We report a 13 year old boy with fragile X syndrome resulting from a de novo deletion of the FMR1 and FMR2 genes extending from (and including) DXS7536 proximally to FMR2 distally. The patient has severe developmental delay, epilepsy, and behavioural difficulties, including autistic features. He has epicanthic folds, in addition to facial features typical of fragile X syndrome, and marked joint hypermobility. We compare our patient to the three other cases reported in which both FMR1 and FMR2 are deleted. This case has the smallest deletion reported to date. All four patients have epilepsy and a more severe degree of mental retardation than is usual in fragile X syndrome resulting from FMR1 triplet repeat expansion. Three of the patients have joint laxity and two have epicanthic folds. We suggest that these features, in particular severe developmental delay and epilepsy, may form part of the characteristic phenotype resulting from deletion of both FMR1 and FMR2 genes. The diagnosis in this case was delayed because routine cytogenetics showed no abnormality and standard molecular tests for FMR1 triplet repeat expansion (PCR and Southern blotting) failed. Further DNA studies should be undertaken to investigate for a deletion where clinical suspicion of fragile X syndrome is strong and routine laboratory tests fail. (J Med Genet 1999;36:565–566)

Keywords: fragile X; FMR1; FMR2; deletion

Case report
The patient was born after an uneventful pregnancy by elective caesarian section for breech presentation. His birth weight was 4692 g and there were no perinatal problems. There was no relevant family history. Severe developmental delay became evident in the first year of life. He sat at 10 months and walked at 2 years 10 months. Now aged 13 years, he can speak in short sentences and has behavioural difficulties, with aggression and agitation. He also has autistic features including a dislike of change in routine and hand flapping. Since 2½ years he has had severe polymorphic epilepsy which has been difficult to control despite several anti-convulsant medications.

Figure 1 The proband. Note (A) prominent forehead and jaw and epicanthic folds, (B) prominent ears, and (C) marked joint laxity. (Photographs reproduced with permission.)
On examination, he has a large head (circumference above the 97th centile), a long face with prominent forehead and jaw, epicanthic folds, large ears, and marked joint hypermobility (fig 1). He also has a convergent squint.

The karyotype was normal including culture in folate deficient medium. Routine molecular analysis by polymerase chain reaction (PCR) and Southern blotting using techniques designed to assess the size of the FMR1 triplet repeat region failed to produce a result.

Further molecular investigation of regions flanking the gene showed that this was because of a de novo deletion of the entire FMR1 and FMR2 genes extending from (and including) DXS7536 proximally to FMR2 distally (fig 2).

## Discussion

Table 1 compares our patient with the other cases reported in which both FMR1 and FMR2 are deleted. He has the smallest deletion reported to date.

Epilepsy is seen in all four patients with deletions of both FMR1 and FMR2, who also have more severe intellectual impairment and a greater degree of joint laxity than is usual in patients with fragile X syndrome owing to FMR1 triplet repeat expansion. Our patient has epicanthus which is also seen in the case of Tarleton et al and Albright et al. In patients with deletion of FMR1 but intact FMR2, severe epilepsy and marked joint laxity are not common. These patients often have typical facial features, and the occurrence of atypical features such as eunuchoid habitus, cherubism, prominent occiput with double hair whorl, shawl scrotum, and anal atresia may be the result of deletion of other adjoining genes.

The FMR2 associated phenotype is said to be milder than that caused by loss of expression of FMR1. However, losing both FMR1 and FMR2 genes appears to cause a more severe disorder of brain development. The clinical features shared by our patient and those previously reported with FMR1 and FMR2 deletions, in particular moderate to severe developmental delay and epilepsy, suggest that these may be characteristic features which result from loss of both these genes. Further case reports will help to define this phenotype more clearly.

Finally, it should be noted that the diagnosis in our patient was delayed because routine laboratory investigations were negative (cytogenetics) or failed (DNA). Further investigations of DNA from the child and his mother indicated that the “failure” of the routine DNA test was the result of a de novo deletion in the child. It is important to be aware of this mechanism and to undertake further DNA studies if there is a strong clinical suspicion of fragile X syndrome.

---

Table 1 Comparison of clinical features in patients with deletion of FMR1 and FMR2

<table>
<thead>
<tr>
<th>Feature</th>
<th>Our patient</th>
<th>Wolff et al 6</th>
<th>Wolff et al 6</th>
<th>Tarleton et al 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental retardation</td>
<td>Severe</td>
<td>Yes, severe</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>Profound</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Joint laxity</td>
<td>Marked</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Epicanthic folds</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Approximate length of deletion</td>
<td>6.6 Mb</td>
<td>13 Mb</td>
<td>11.3 Mb</td>
<td>10.3 Mb</td>
</tr>
</tbody>
</table>

On examination, he has a large head (circumference above the 97th centile), a long face with prominent forehead and jaw, epicanthic folds, large ears, and marked joint hypermobility (fig 1). He also has a convergent squint.

The karyotype was normal including culture in folate deficient medium. Routine molecular analysis by polymerase chain reaction (PCR) and Southern blotting using techniques designed to assess the size of the FMR1 triplet repeat region failed to produce a result.

Further molecular investigation of regions flanking the gene showed that this was because of a de novo deletion of the entire FMR1 and FMR2 genes extending from (and including) DXS7536 proximally to FMR2 distally (fig 2).

## Discussion

Table 1 compares our patient with the other cases reported in which both FMR1 and FMR2 are deleted. He has the smallest deletion reported to date.

Epilepsy is seen in all four patients with deletions of both FMR1 and FMR2, who also have more severe intellectual impairment and a greater degree of joint laxity than is usual in patients with fragile X syndrome owing to FMR1 triplet repeat expansion. Our patient has epicanthus which is also seen in the case of Tarleton et al and Albright et al.

In patients with deletion of FMR1 but intact FMR2, severe epilepsy and marked joint laxity are not common. These patients often have typical facial features, and the occurrence of atypical features such as eunuchoid habitus, cherubism, prominent occiput with double hair whorl, shawl scrotum, and anal atresia may be the result of deletion of other adjoining genes.

The FMR2 associated phenotype is said to be milder than that caused by loss of expression of FMR1. However, losing both FMR1 and FMR2 genes appears to cause a more severe disorder of brain development. The clinical features shared by our patient and those previously reported with FMR1 and FMR2 deletions, in particular moderate to severe developmental delay and epilepsy, suggest that these may be characteristic features which result from loss of both these genes. Further case reports will help to define this phenotype more clearly.

Finally, it should be noted that the diagnosis in our patient was delayed because routine laboratory investigations were negative (cytogenetics) or failed (DNA). Further investigations of DNA from the child and his mother indicated that the “failure” of the routine DNA test was the result of a de novo deletion in the child. It is important to be aware of this mechanism and to undertake further DNA studies if there is a strong clinical suspicion of fragile X syndrome.